Is POZN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

644 people get POZN articles and Market Currents by email alert.

Get email alerts on POZN »

HEADLINES:

POZEN to Present at the Jefferies 2013 Global Healthcare Conference

Business Wire (Thu, 7:30AM)
Presence of Gastric Erosions in Patients Taking Low-Dose Aspirin for Secondary Cardiovascular Prevention May Result in a 2-Fold Increase in Future Gastric Ulcers

Business Wire (Tue, 7:30AM)
POZEN's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Pounding The Table On Pozen: Why There's Upside In This Misunderstood Name
PropThink • Wed, May 8 • 4 Comments
POZEN Reports First Quarter 2013 Results

Business Wire (May 8, 2013)
POZEN Announces May 8th Webcast of First Quarter 2013 Results

Business Wire (Apr 30, 2013)
POZEN's CEO Hosts Analyst and Investor Update Conference (Transcript)
Thu, Apr 18
POZEN to Host Analyst and Investor Update Webcast

Marketwire (Apr 9, 2013)
POZEN Announces Results from a Burden of Cardiovascular Disease Study: a Managed Care Perspective

Business Wire (Apr 5, 2013)
POZEN Submits New Drug Application for PA32540/PA8140

Business Wire (Mar 27, 2013)
POZEN Reports European Patent Office Maintains PA/VIMOVO Patent

Business Wire (Mar 12, 2013)
POZEN to Present at the 25th Annual ROTH Conference

Business Wire (Mar 7, 2013)
A Deal For Pozen's PA Could Send Shares Soaring
Jason Napodano • Wed, Mar 6 • 7 Comments
POZEN's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 6
POZEN Reports Fourth Quarter & Year End 2012 Results

Business Wire (Mar 6, 2013)
The Dendreon Bear Raid Of 2009: Chasing The Perpetrators
Theodore Cohen • Mon, Mar 4 • 44 Comments
POZEN Announces March 6th Webcast of Fourth Quarter and Year End 2012 Results

Business Wire (Feb 27, 2013)
3 Attractively Valued Biotechs From BIO CEO 2013
Brian L. Wilson • Thu, Feb 14
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen
Scott Matusow • Wed, Feb 13 • 13 Comments
4 Small Cap Biopharmas With Near-Term Catalysts
Scott Matusow • Mon, Feb 11 • 22 Comments

To learn more about Seeking Alpha Pro, click here.

Pounding The Table On Pozen: Why There's Upside In This Misunderstood Name
PropThink • Wed, May 8 • 4 Comments
A Deal For Pozen's PA Could Send Shares Soaring
Jason Napodano • Wed, Mar 6 • 7 Comments
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen
Scott Matusow • Wed, Feb 13 • 13 Comments
Understanding The Market Opportunity For Pozen's Safer Aspirin
PropThink • Wed, Jan 16 • 13 Comments
Pozen's Safer Aspirin Pipeline Looks Promising
C.R. Jackson • Mon, Nov 12, 2012
Buy Pozen Ahead Of Key Medical Meetings
Jason Napodano • Mon, Sep 24, 2012 • 12 Comments
Pozen Shares On The Rebound Since European Migraine Licensing Deal
M. E. Garza • Mon, May 14, 2012 • 1 Comment
FDA Throws Pozen A Curveball
Jason Napodano • Fri, Apr 27, 2012 • 10 Comments
Pozen's Final Results On Ulcer Safe Aspirin Can Send Shares Soaring
Roy Manning III • Tue, Mar 20, 2012 • 4 Comments
Pozen Has No Debt And Plenty Of Resources For 2012 NDA Filing
M. E. Garza • Tue, Nov 29, 2011 • 2 Comments
Pozen Deal Unlocks Value
Jason Napodano • Mon, Nov 28, 2011
Pozen's Success Will Depend on Execution of Unique Marketing Strategies
Jason Chew • Sun, Mar 13, 2011 • 4 Comments
What's Pozen Really Worth?
Jason Napodano • Tue, Mar 8, 2011 • 26 Comments
4 Biotech Clearance Rack Stocks
Joseph Krueger • Mon, Jun 14, 2010 • 60 Comments
Pozen Poised to Fill a Healthcare Void
Investment U • Sun, Feb 1, 2009 • 2 Comments
Pozen, Inc. on the Verge of Recovery
Maulik Nagri • Wed, Oct 10, 2007
Pozen's Trexima Begins Six Month FDA Review
Anthony Payne • Tue, Apr 10, 2007
Pozen: On Track With New Pain Medications
Zacks Investment Research • Mon, Mar 12, 2007
Pozen's Volatility Is Reason Enough To Stay Away (POZN)
Roger Nusbaum • Mon, Jun 12, 2006

The Dendreon Bear Raid Of 2009: Chasing The Perpetrators
Theodore Cohen • Mon, Mar 4 • 44 Comments
3 Attractively Valued Biotechs From BIO CEO 2013
Brian L. Wilson • Thu, Feb 14
4 Small Cap Biopharmas With Near-Term Catalysts
Scott Matusow • Mon, Feb 11 • 22 Comments
8 High Growth Stocks At A Big Discount And With Low PEG, Low Debt
Arie Goren • Wed, Dec 26, 2012 • 20 Comments
6 Growth Stocks With Big Upside Potential
Arie Goren • Fri, Nov 23, 2012 • 5 Comments
6 Oversold High-Growth Stocks Ready To Bounce
Arie Goren • Sun, Nov 11, 2012
3 Growth Stocks With Positive Momentum
Arie Goren • Fri, Sep 28, 2012
Watch Out For The One-Time Revenue Effect
MagicDiligence • Fri, Sep 14, 2012 • 11 Comments
4 Low-Debt Healthcare Stocks Raking In Profits
ZetaKap • Fri, Sep 14, 2012
Hedge Funds Love These 3 High-Growth Drugmakers
Kapitall • Fri, Aug 10, 2012 • 1 Comment
4 Highly Undervalued Stocks With Bullish Short Trends
Kapitall • Tue, Jul 31, 2012
4 Healthcare Stocks Fueling Growth On Strong Profitability
ZetaKap • Tue, Jul 3, 2012 • 2 Comments
4 Undervalued Healthcare Stocks Ready To Rally
Leonid Kanopka • Mon, Jun 25, 2012 • 2 Comments
4 Undervalued Must Haves
Leonid Kanopka • Fri, Jun 22, 2012 • 1 Comment
7 Healthcare Stocks Undervalued By Graham Number And Earnings Growth
Kapitall • Wed, Jun 20, 2012 • 1 Comment
5 Healthcare Stocks Commanding Profits And Poised For Strong Growth
ZetaKap • Tue, Jun 5, 2012 • 9 Comments
6 Healthcare Stocks Undervalued By Earnings Growth, The Graham Number
Kapitall • Sun, May 20, 2012
21 Undervalued, Highly Shorted Stocks Being Bought Up By Hedge Funds
Kapitall • Sun, May 13, 2012 • 2 Comments
9 Undervalued Healthcare Stocks Being Snapped Up By Hedge Funds
Kapitall • Sun, Apr 29, 2012
21 Outperforming Hedge Fund Stock Picks Reporting Earnings Next Week
Kapitall • Thu, Apr 26, 2012

POZEN's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
POZEN's CEO Hosts Analyst and Investor Update Conference (Transcript)
Thu, Apr 18
POZEN's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 6
POZEN's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
POZEN's CEO Hosts Update Conference Call (Transcript)
Fri, Aug 24, 2012
POZEN's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 1, 2012
Pozen CEO Discusses Q3 2010 Results - Earnings Call Transcript
Sat, Oct 30, 2010
POZEN Inc Q2 2010 Earnings Call Transcript
Tue, Aug 3, 2010
POZEN Inc. Q1 2010 Earnings Call Transcript
Mon, May 3, 2010
POZEN Q4 2008 Earnings Call Transcript
Wed, Feb 25, 2009
POZEN Inc. Q3 2008 Earnings Call Transcript
Wed, Nov 12, 2008
POZEN, Inc. Q2 2008 Earnings Call Transcript
Mon, Aug 25, 2008
POZEN Inc. Q1 2008 Earnings Call Transcript
Thu, May 8, 2008

POZEN to Present at the Jefferies 2013 Global Healthcare Conference

Business Wire (Thu, 7:30AM)
Presence of Gastric Erosions in Patients Taking Low-Dose Aspirin for Secondary Cardiovascular Prevention May Result in a 2-Fold Increase in Future Gastric Ulcers

Business Wire (Tue, 7:30AM)
POZEN Reports First Quarter 2013 Results

Business Wire (May 8, 2013)
POZEN Announces May 8th Webcast of First Quarter 2013 Results

Business Wire (Apr 30, 2013)
POZEN to Host Analyst and Investor Update Webcast

Marketwire (Apr 9, 2013)
POZEN Announces Results from a Burden of Cardiovascular Disease Study: a Managed Care Perspective

Business Wire (Apr 5, 2013)
POZEN Submits New Drug Application for PA32540/PA8140

Business Wire (Mar 27, 2013)
POZEN Reports European Patent Office Maintains PA/VIMOVO Patent

Business Wire (Mar 12, 2013)
POZEN to Present at the 25th Annual ROTH Conference

Business Wire (Mar 7, 2013)
POZEN Reports Fourth Quarter & Year End 2012 Results

Business Wire (Mar 6, 2013)
POZEN Announces March 6th Webcast of Fourth Quarter and Year End 2012 Results

Business Wire (Feb 27, 2013)
POZEN Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference

Business Wire (Feb 8, 2013)
POZEN to Present at the 24th Annual Piper Jaffray Healthcare Conference

Business Wire (Nov 19, 2012)
POZEN Announces Positive Results for the PA8140-102 Bioavailability Study

Business Wire (Nov 15, 2012)
POZEN Reports Third Quarter 2012 Financial Results and Positive PA32540 Clinical Updates

Business Wire (Nov 8, 2012)
POZEN Presents Positive PA32540 Pivotal Phase 3 Data at the American Heart Association Scientific Sessions 2012

Business Wire (Nov 6, 2012)
POZEN Announces November 8th Webcast of Third Quarter 2012 Results and November 6th Presentation of Phase 3 Results for PA32540 at AHA’s Scientific Sessions 2012

Business Wire (Oct 29, 2012)
POZEN Patents Upheld in Treximet Patent Litigation Appeal

Business Wire (Oct 1, 2012)
POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen in a Phase 1 Study (“Co-Rx”)

Business Wire (Aug 29, 2012)
POZEN to Present at the 2012 Stifel Nicolaus Healthcare Conference

Business Wire (Aug 27, 2012)

POZN vs. ETF Alternatives

Company Description

Currently, there's no company description for POZN.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 11:35 AM Pozen (POZN -8.8%) falls after Q1 results miss estimates. The company says AstraZeneca (AZN), —which commercializes the osteoarthritis drug on which POZN receives royalties — plans to cease promotion of VIMOVO in the U.S. and Europe (ex-Spain and Portugal), although the product will still be available. Promotions will only continue in countries which account for 47% of Q1 sales. POZN says it is "unsure of the impact" the strategy change will have on future financial performance, but it is worth noting POZN derives all of its revenue from VIMOVO royalties. (PR) Comment! [Healthcare, On the Move, Earnings]
Wednesday, May 8, 7:34 AM POZEN (POZN): Q1 EPS of -$0.19 misses by $0.02. Revenue of $1.41M misses by $0.02M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 8, 12:05 AM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
Tuesday, May 7, 5:30 PM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
Wednesday, March 27, 8:30 AM Pozen (POZN) submits NDA for its proprietary aspirin/omeprazole combination tablets PA32540 and PA8140. The drugs are intended to improve the "benefit/risk profile" of aspirin for those "at risk of developing gastric ulcers." (See: Deal for Pozen's PA) Comment! [Healthcare]
Wednesday, March 6, 12:02 PM Pozen (POZN -1.7%) slips after its Q4 comes in slightly below Street expectations. In its earnings call, the company said it is preparing a new drug application for investigational products containing enteric-coated aspirin and immediate release omeprazole, including two dosage forms, PA32540 containing 325 mg of aspirin and PA8140, a low dose formulation containing 81 mg aspirin. It continues to expect filing for both products no later than Q2 FY13. (Conference Call Webcast) Comment! [Healthcare, Earnings, On the Move]
Wednesday, March 6, 7:36 AM Pozen (POZN): Q4 EPS of -$0.20 beats by $0.01. Revenue of $1.4M in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, March 6, 12:05 AM Notable earnings before Wednesday’s open: AEO, AMRC, BF.B, BIG, END, HOV, POZN, SPLS, TFM, WMC, WRES Comment! [Earnings]
Tuesday, March 5, 5:30 PM Notable earnings before Wednesday’s open: AEO, AMRC, BF.B, BIG, END, HOV, POZN, SPLS, TFM, WMC, WRES Comment! [Earnings]
Friday, November 16, 2012, 11:37 AM Pozen (POZN -1.1%) gives back the early morning gains it racked up today, after reporting positive Phase I testing results of its PA8140-102 drug candidate - a proprietary combination of aspirin and omeprazole, used to treat acid reflux, pectic ulcer and other gastroesophageal problems. It also says that it's successfully manufactured the PA8140 tablet batches, required for the primary NDA stability program. POZN is targeting an NDA submission for the drug no later than the end of April 2013. Comment! [Healthcare]
Friday, November 9, 2012, 2:11 PM Pozen (POZN +10.3%) moves up on an upgrade to Strong Buy at Ascendiant Capital. The firm says the recent pullback in share price following its Q3 earnings miss yesterday has created a buying opportunity. Comment! [Healthcare, Earnings, On the Move]
Thursday, November 8, 2012, 7:57 AM Pozen (POZN): Q3 EPS of -$0.19 misses by $0.04. Revenue of $940K (-81.6% Y/Y). (PR) Comment! [Earnings, Healthcare]
Thursday, November 8, 2012, 12:05 AM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN Comment! [Earnings]
Wednesday, November 7, 2012, 5:30 PM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN 1 Comment [Earnings]
Tuesday, November 6, 2012, 6:11 PM Pozen (POZN) presents positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, a treatment for gastric ulcers, at The American Heart Association Scientific Sessions 2012. The drug, which consists of a tablet with enteric-coated aspirin coupled with immediate-release Omeprazole, showed that patients on PA32540 experienced fewer gastric ulcers compared to those taking enteric-coated aspirin alone. 1 Comment [Healthcare]
Thursday, October 4, 2012, 5:50 PM Pozen (POZN) says the U.S. Court of Appeals has upheld the Texas District Court's ruling that had originally found in favor of POZN against several generic pharmaceutical companies which had filed Abbreviated New Drug Applications seeking FDA approval to market generic copies of Treximet. Treximet is marketed by POZN's exclusive U.S. licensee, GlaxoSmithKline (GSK). Comment! [Healthcare]

Scott Matusow
$POZN $6.02 should test $6.50 soon
Feb 12, 10:06 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$POZN CEO presentation for today>> Sales growth plus April filing plus >$400 million market opp. confirmed http://bit.ly/Y6AQuK
Feb 12, 8:56 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$POZN also filing for PA810 soon, which is a doctor preferred 81 mg dose of "safer" aspirin. Totally forgot that in my article -- my bad.
Feb 11, 2:29 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Trade call: $POZN. Price Target opinion $6.50, higher on news of a partner which should be coming soon
Feb 11, 11:45 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Low-Debt Healthcare Stocks Raking In Profits http://bit.ly/RWUMlj $BDSI $MNTA $POZN $TARO @ZetaKap
9/14/12
Reply (1)

• !Report Abuse
View all 1 replies
Retail Investor: $TARO shareholders pls read this before casting your vote http://bit.ly/ST8vWQ
10/6/12
• !Report Abuse
Add a reply...

140 characters

MagicDiligence
New article: Watch out for the "one-time revenue effect" with Magic Formula stocks. $LMLP $MAXY $POZN $MBLX http://bit.ly/SKQsbb
9/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/f2AV New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, $AMRN, $HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN, $SLXP
7/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/ObIXDN New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, /4HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN
7/19/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: AMRN
7/19/12
• !Report Abuse
Add a reply...

140 characters

ZetaKap
4 Healthcare Stocks Fueling Growth On Strong Profitability http://bit.ly/N8eV5c $PGNX $FRX $POZN $ELN @ZetaKap
7/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Healthcare Stocks Commanding Profits And Poised For Strong Growth http://bit.ly/KaBeZr $AKRX $PGNX $POZN $QCOR $SIGA @ZetaKap
6/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

ZetaKap
4 Low-Debt Healthcare Stocks Raking In Profits http://bit.ly/RWUMlj $BDSI $MNTA $POZN $TARO @ZetaKap
9/14/12
Reply (1)

• !Report Abuse
View all 1 replies
Retail Investor: $TARO shareholders pls read this before casting your vote http://bit.ly/ST8vWQ
10/6/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/ObIXDN New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, /4HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN
7/19/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: AMRN
7/19/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Pozen (POZN) is soaring 44% after selling "U.S. royalties right for $75 mln." Not bad for a $108 million company. http://reut.rs/uFwH5V
11/25/11
Reply (1)

• !Report Abuse
View all 1 replies
lowemoran: Lol! I thought it said Ponzi....
11/25/11
• !Report Abuse
Add a reply...

140 characters

POZN Pozen, Inc.

POZN

Pozen, Inc.